<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="et DéveloppementInstitut de Recherche pour le DéveloppementUniversité Paris DescartesInsermParisFrance[8], Africa" exact="Health Research" post="InstituteSomkheleSouth Africa[9], University of BotswanaGaboroneBotswana[10], Department of Global Health"/>
 <result pre="Global Health &amp;amp; InfectionBrighton and Sussex Medical SchoolBrightonUnited Kingdom[11], Africa" exact="Health Research" post="InstituteKwaZulu‐NatalSouth Africa[12], Research Department of Infection and Population HealthUniversity"/>
 <result pre="and Population HealthUniversity College LondonLondonUnited Kingdom[13], Imperial CollegeNational Institute for" exact="Health Research" post="Biomedical Research CenterLondonUnited Kingdom[14], Department of Infectious DiseaseImperial College"/>
 <result pre="sub‐Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by" exact="World Health Organization" post="guidelines and the UNAIDS 90‐90‐90 campaign. Discussion These three‐year"/>
 <result pre="HIV prevention HIV care continuum public health universal access Funding" exact="National Institutes of Health" post="(NIAID, NIDA, NIMH) President's Emergency Plan for AIDS Relief,"/>
 <result pre="Health (NIAID, NIDA, NIMH) President's Emergency Plan for AIDS Relief," exact="Gilead Sciences," post="Bill and Melinda Gates Foundation French National Agency for"/>
 <result pre="NIDA, NIMH) President's Emergency Plan for AIDS Relief, Gilead Sciences," exact="Bill and Melinda Gates Foundation" post="French National Agency for Research on AIDS and Viral"/>
 <result pre="a dynamic period of UNAIDS global campaigns and changes in" exact="World Health Organization" post="(WHO) ART guidelines. In 2014, UNAIDS launched the 90‐90‐90"/>
 <result pre="has received research grants and honorarium for consulting services from" exact="Gilead Sciences." post="Dr. Diane V. Havlir reports receiving non‐financial support from"/>
 <result pre="Sciences. Dr. Diane V. Havlir reports receiving non‐financial support from" exact="Gilead Sciences." post="Authors' contributions DH and FD wrote the first draft"/>
 <result pre="which this article is based on was funded by the" exact="National Institutes of Health" post="(NIAID, NIDA, NIMH), President's Emergency Plan for AIDS Relief,"/>
 <result pre="Health (NIAID, NIDA, NIMH), President's Emergency Plan for AIDS Relief," exact="Gilead Sciences," post="Bill and Melinda Gates Foundation, French National Agency for"/>
 <result pre="NIDA, NIMH), President's Emergency Plan for AIDS Relief, Gilead Sciences," exact="Bill and Melinda Gates Foundation," post="French National Agency for Research on AIDS and Viral"/>
 <result pre="in sub‐Saharan Africa. J Int AIDS Soc. 2018;21:e25048. 12collab: Joint" exact="United Nations" post="Programme on HIV/AIDS . 90–90‐90–An ambitious treatment target to"/>
 <result pre="Switzerland; 2014 [cited 2019 Nov 10]. Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf 13collab:" exact="World Health Organization" post="(WHO) . Consolidated guidelines on the use of antiretroviral"/>
 <result pre="Switzerland; 2013 [cited 2019 Nov 10]. Available from: https://www.who.int/hiv/pub/guidelines/arv2013/download/en/ 14collab:" exact="World Health Organization" post="(WHO) . Guideline on when to start antiretroviral therapy"/>
 <result pre="at long last. N Engl J Med. 2019;380(21):1985–7.31042822 25collab: Joint" exact="United Nations" post="Programme on HIV/AIDS . UNAIDS Data 2019 Joint United"/>
 <result pre="United Nations Programme on HIV/AIDS . UNAIDS Data 2019 Joint" exact="United Nations" post="Programme on HIV/AIDS. [Internet] Geneva, Switzerland; 2019 [cited 2019"/>
</results>
